Antibody-drug conjugates (ADC) delivering
pyrrolobenzodiazepine (PBD)
DNA cross-linkers are currently being evaluated in clinical trials, with encouraging results in Hodgkin and non-Hodgkin
lymphomas. The first example of an ADC delivering a PBD
DNA cross-linker (
loncastuximab tesirine) has been recently approved by the FDA for the treatment of relapsed and refractory
diffuse large B-cell lymphoma. There has also been considerable interest in mono-alkylating PBD analogs. We conducted a head-to-head comparison of a conventional PBD bis-
imine and a novel PBD mono-
imine. Key Mitsunobu chemistry allowed clean and convenient access to the mono-
imine class. Extensive
DNA-binding studies revealed that the mono-
imine mediated a type of
DNA interaction that is described as "pseudo cross-linking," as well as alkylation. The PBD mono-
imine ADC demonstrated robust antitumor activity in mice bearing human
tumor xenografts at doses 3-fold higher than those that were efficacious for the PBD bis-
imine ADC. A single-dose toxicology study in rats demonstrated that the MTD of the PBD mono-
alkylator ADC was approximately 3-fold higher than that of the ADC bearing a bis-
imine payload, suggesting a comparable therapeutic index for this molecule. However, although both ADCs caused myelosuppression, renal toxicity was observed only for the bis-
imine, indicating possible differences in toxicologic profiles that could influence tolerability and therapeutic index. These data show that mono-
amine PBDs have physicochemical and pharmacotoxicologic properties distinct from their cross-linking analogs and support their potential utility as a novel class of ADC payload.